Clinical Trials in New York

Showing 11541-11560 of 19,464 trials

Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma

NCT03193918

This is a single-arm phase I/Ib study of crenolanib combined with ramucirumab/paclitaxel as second line therapy for patients with advanced/metastatic adenocarcinoma of the esophagus, GEJ or stomach. Patients will be enrolled in two phases; dose escalation phase and dose expansion phase.

Esophagogastric Adenocarcinoma

Arog Pharmaceuticals, Inc.30 participantsStarted Apr 2017

New York, New York, United States

COMPLETEDPhase 1/2< 1 mile

Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment

NCT03672240

A Phase Ib, open label, non randomized study to measure the safety and PK characteristics of APL-1202 at steady-state in adult male and female BCG resistant NMIBC patients when it is administered alone and concurrently with BCG.

Non-Muscle Invasive Bladder Cancer (NMIBC)

Asieris Pharmaceutical Technologies Co., Ltd.6 participantsStarted Nov 2018

New York, New York, United States • Myrtle Beach, South Carolina, United States

TERMINATEDPhase 1/2< 1 mile

A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

NCT03026166

The purpose of this study is to assess the safety and efficacy of rovalpituzumab tesirine administered in combination with nivolumab or nivolumab and ipilimumab in participants with extensive-stage small cell lung cancer (SCLC).

Small Cell Lung Cancer

AbbVie42 participantsStarted Mar 2017

La Jolla, California, United States • Orlando, Florida, United States • Athens, Georgia, United States +32 more locations

Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma

Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment

A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

Find Trials by Condition in New York

Phase 2B Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)

Tailored Approaches to Stroke Health Education

Effect of Intervention to Improve Stroke Recognition

Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy

Intra-oral Treatment of OLP With Rivelin®-CLO Patches

Emotion Regulation Therapy to Address Distress Among Caregivers

Brain Sleep Deprivation MRI Effects (BEDTIME)

Effects of Brain-stimulation on Metamemory Monitoring and Control

Growth and Tolerance of Infants Fed Formula for 16 Weeks

Expanded Access for ACE-011

A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2

Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer

Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer

A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer

Bronchial Thermoplasty 10+ Year Study

A Study to Look at the Efficacy and Safety of Keppra® Extended Release Formulation - XR